Grupo Español de Leucemia Linfocítica Crónica (GELLC) Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04608318
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Grupo Español de Leucemia Linfocítica Crónica (GELLC)

Active Ingredients

Drugs in Phase 3 Trials (3)

ibrutinib (imbruvica) (1 trial)

obinutuzumab (gazyva) (1 trial)

venetoclax (venclexta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3